Health ❯ Medicine ❯ Pharmacology

Drug Development

Clinical Trials Cancer Treatment Weight Loss Drugs Alzheimer's Disease Targeted Therapies Antibiotics Baxdrostat Obesity Treatment Experimental Drugs Combination Therapy

3 ARTICLES

last wk.

ETH Zurich Pins GRK2 Aggregation as Alzheimer’s Target and Reveals 'Compound 10' That Slows Decline in Mice

Preclinical results show the small molecule prevents GRK2 clumping, restores mitochondrial function and lowers amyloid‑beta while the lab seeks a commercial partner for development.

4 ARTICLES

last wk.

Flu Drug Class Prevents Glycan Loss Linked to Cognitive Decline in People With HIV

3 ARTICLES

3w ago

Asthma Drug Montelukast Restores Checkpoint Response in Preclinical Cancer Models

7 ARTICLES

last mo.

Oral GLP-1 Weight-Loss Pills Curb Hedonic Eating by Hitting Deep-Brain Circuit in Mice

4 ARTICLES

last mo.

Five-Target ‘Trojan Horse’ Drug Outperforms Leading Incretins in Obese Diabetic Mice

10 ARTICLES

last mo.

Brazil Moves to Tighten Rules on GLP‑1 Weight‑Loss Pens as Demand Surges

5 ARTICLES

last mo.

Mouse Study Maps Serotonin Circuit That Triggers Tinnitus-Like Signals

3 ARTICLES

2mo ago

TIE2 Identified as Drug Target in Brain Cavernous Malformations After Mouse Study Stops New Lesions

3 ARTICLES

2mo ago

Arvinas’ ARV-102 Hits >50% LRRK2 Degradation in Phase 1 Parkinson’s Trial

4 ARTICLES

3mo ago

Sildenafil Shows Early Benefit in Leigh Syndrome as Europe-Wide Trial Is Planned

8 ARTICLES

3mo ago

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

7 ARTICLES

4mo ago

Anti-Seizure Drug Levetiracetam Blocks Early Alzheimer’s Protein Production, Study Finds

3 ARTICLES

4mo ago

Immune Cell Stress Switch Implicated in Chemo Neuropathy, With Existing Inhibitors Poised for Tests

9 ARTICLES

7mo ago

First New Antimalarial in Decades Tops 97% Cure in Phase III as Novartis Seeks Approval

6 ARTICLES

7mo ago

Roche’s Oral BTK Drug Succeeds in Phase 3 MS Trials, Matching Ocrevus in Progressive Disease

3 ARTICLES

7mo ago

AstraZeneca’s Baxdrostat Lowers 24-Hour Systolic BP by 14 mmHg in Phase 3, AHA Presentation Confirms

Drug Development

ETH Zurich Pins GRK2 Aggregation as Alzheimer’s Target and Reveals 'Compound 10' That Slows Decline in Mice

Flu Drug Class Prevents Glycan Loss Linked to Cognitive Decline in People With HIV

Asthma Drug Montelukast Restores Checkpoint Response in Preclinical Cancer Models

Oral GLP-1 Weight-Loss Pills Curb Hedonic Eating by Hitting Deep-Brain Circuit in Mice

Five-Target ‘Trojan Horse’ Drug Outperforms Leading Incretins in Obese Diabetic Mice

Brazil Moves to Tighten Rules on GLP‑1 Weight‑Loss Pens as Demand Surges

Mouse Study Maps Serotonin Circuit That Triggers Tinnitus-Like Signals

TIE2 Identified as Drug Target in Brain Cavernous Malformations After Mouse Study Stops New Lesions

Arvinas’ ARV-102 Hits >50% LRRK2 Degradation in Phase 1 Parkinson’s Trial

Sildenafil Shows Early Benefit in Leigh Syndrome as Europe-Wide Trial Is Planned

Never miss stories about

Drug Development

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

Anti-Seizure Drug Levetiracetam Blocks Early Alzheimer’s Protein Production, Study Finds

Alzheimer’s Study Finds Memory “Replay” Persists but Loses Structure

Restoring NAD+ Reverses Alzheimer’s Signs in Mice, Study Finds

Researchers Engineer ‘Mild’ Mitochondrial Uncouplers in Preclinical Study

Approved Lymphoma Drug Helps Overcome Resistance in Neuroblastoma Models

Immune Cell Stress Switch Implicated in Chemo Neuropathy, With Existing Inhibitors Poised for Tests

First New Antimalarial in Decades Tops 97% Cure in Phase III as Novartis Seeks Approval

Roche’s Oral BTK Drug Succeeds in Phase 3 MS Trials, Matching Ocrevus in Progressive Disease

AstraZeneca’s Baxdrostat Lowers 24-Hour Systolic BP by 14 mmHg in Phase 3, AHA Presentation Confirms

Never miss stories about

Drug Development